Model-Driven Genetic Design And Bioprocess Optimization Across Modalities

At the Bioprocessing Summit 2025, Raja Srinivas, Co-Founder of Asimov Inc., addressed a critical bottleneck in the industry: the reliance on "one-size-fits-all" expression vectors and empirical process optimization. While standard, these traditional methods restrict productivity and delay the commercialization of complex therapeutic modalities.

Overcoming these development hurdles requires a shift toward the end-to-end design of genetic systems, cell lines, and bioprocesses. By utilizing a portfolio of mechanistic, AI-based, and hybrid models, developers can move away from iterative guesswork and toward predictive precision. This approach effectively accelerates time to clinic while enhancing overall process performance. Watch the full presentation to examine case studies demonstrating this methodology across monoclonal antibodies and viral vectors.